["Allergy, Intolerance": "Beta Blocker Therapy Ingredient"]

Performance/Reporting Period

2021

Value Set Description from VSAC

Clinical Focus: This value set contains concepts that represent beta blocker therapy ingredients.
Data Element Scope: This value set may use Quality Data Model (QDM) category related to Allergy/Intolerance.
Inclusion Criteria: Includes only relevant concepts associated with prescribable ingredient only.
Exclusion Criteria: No exclusions.

Constrained to codes in the Allergy, Intolerance: Beta Blocker Therapy Ingredient value set (2.16.840.1.113883.3.526.3.1493)

QDM Datatype and Definition (QDM Version 5.5 Guidance Update)

"Allergy Intolerance"

Data elements that meet criteria using this datatype should document the allergy or intolerance and its corresponding value set.

Timing:

The prevalence period references the time from the onset date to the abatement date. Often an abatement date is not present as allergy or intolerance is ongoing.
The author dateTime references the recorded time.

eCQMs using this data element:

CMS144v9 - Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

CMS145v9 - Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF less than 40%)

QDM Attributes

prevalencePeriod

Prevalance Period is the time from onset dateTime to abatement dateTime.